Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?

Transplantation

Volumn 94, Issue 3, 2012, Pages 295-301

  Peterlin, Pierre ^a   Leux, Christophe ^a   Gastinne, Thomas ^a   Roland, Virginie ^a   Mahé, Béatrice ^a   Dubruille, Viviane ^a   Delaunay, Jacques ^a   Chevallier, Patrice ^a   Guillaume, Thierry ^a   Blin, Nicolas ^a   Ayari, Sameh ^a   Clavert, Aline ^a   Mohty, Mohamad ^a   Dousset, Christelle ^a   Milpied, Noel ^b   Harousseau, Jean Luc ^c   Moreau, Philippe ^a   Wuilleme, Soraya ^a   Moreau, Anne ^a   Le Gouill, Steven ^a,d  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d Team 12   (France)

Author keywords

Autologous stem cell transplantation; Mantle cell lymphoma; Total body irradiation

Indexed keywords

CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; MELPHALAN; PREDNISONE; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCORING SYSTEM; SURVIVAL RATE; WHOLE BODY RADIATION;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINS; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 84864667671     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318256dcba     Document Type: Article

References (40)

1. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7: 750.
2. Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011; 117: 26.
3. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stagemantle cell lymphoma. J ClinOncol 2009; 27: 511.
4. Forstpointner R,Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064.
5. Lenz G, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984.
6. Schulz H, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic reviewand meta-analysis. J Natl Cancer Inst 2007; 99: 706.
7. Dreyling M, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677.
8. Geisler CH, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687.
9. Khouri IF, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16: 3803.
10. Lefrere F, et al. Sequential chemotherapy regimens followed by highdose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 2004; 89: 1275.
11. Thieblemont C, et al. Chemotherapy with rituximab followed by highdose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 2005; 104: 1434.
12. Damon LE, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27: 6101.
13. Moreau P, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731.
14. Deconinck E, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005; 105: 3817.
15. Milpied N, et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998; 22: 645.
16. Gressin R, et al. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica. 2010; 95: 1350.
17. Lefrere F, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16: 587.
18. Khouri IF, et al. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003; 98: 2630.
19. Gianni AM, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximabpurged stem cell autografting (R-HDS regimen). Blood 2003; 102: 749.
20. Hermine O, et al. Alternating courses of 3-CHOP and 3-DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autolgous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the european mantle cell lymphoma network. Blood 2010; 116: 110. Abstract 110.
21. Howard OM, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288.
22. Romaguera JE, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013.
23. Tam CS, et al. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy inmantle cell lymphoma. Blood 2009; 113: 4144.
24. Rubio M, et al. Is there still a place for total body irradiation (TBI) in the conditioning regimen of autologous stem cell transplantation in mantle cell lymphoma?: a retrospective study fromthe lymphomaworking party of the EBMT. Blood 2010; 116: 688. ASH 2010, Abstract 688.
25. Touzeau C, et al. Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: the Experience of the French SFGM-TC Group. Blood 2010; 116: 2392. Abstract 2392.
26. Budde LE, et al. Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving High-Dose Therapy and Autologous Stem-Cell Transplantation. J Clin Oncol 2011; 29: 3023.
27. Ondrejka SL, et al. Indolent mantle cell leukemia: clinicopathologic variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 2011; 96: 1121.
28. Orchard J, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003; 101: 4975.
29. Fernandez V, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010; 70: 1408.
30. Rule SA, et al. Indolent Mantle-Cell Lymphoma: Immunoglobulin Variable Region Heavy Chain Sequence Analysis Reveals Evidence of Disease 10 Years Prior to Symptomatic Clinical Presentation. J Clin Oncol 2011; 29: 437.
31. Christian B, et al. Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. J Clin Oncol. 2010; 28: e629.
32. Pott C, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2006; 115: 3215.
33. Pott C, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006; 107: 2271.
34. Ladetto M, et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 2006; 12: 1270.
35. Dreyling M, et al. Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference. Leuk Lymphoma. 2010; 51: 1612.
36. Vigouroux S, et al. High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica 2005; 90: 1580.
37. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987.
38. Hoster E, et al. A new prognostic index (MIPI) for patients with advancedstage mantle cell lymphoma. Blood 2008; 111: 558.
39. Solal-Celigny P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258.
40. Cheson BD, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.